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Abstract 
 
Background: Previous systematic reviews have indicated that exercise-based cardiac 
rehabilitation (ExCR) for patients with heart failure (HF) has a beneficial effect on health-
related quality of life (HRQoL) and exercise capacity. However, there is uncertainty 
regarding potential differential effects of ExCR across HF patient subgroups.  
 
Objectives: To undertake an individual participant data (IPD) meta-analysis to; (i) assess the 
impact of ExCR on HRQoL and exercise capacity in patients with HF, and (ii) to investigate 
differential effects of ExCR according to a range of patient characteristics: age, sex, ethnicity, 
New York Heart Association (NYHA) functional class, ischaemic aetiology, ejection 
fraction, and exercise capacity. 
 
Methods: A single dataset was produced, comprising randomised trials where ExCR 
(delivered for 3 weeks or more) was compared with a no exercise control group. Each trial 
provided IPD on HRQoL or exercise capacity (or both), with follow-up of 6 months or more. 
We used one- and two-stage meta-analysis models to investigate the effect of ExCR overall 
and the interactions between ExCR and participant characteristics.  
 
Results: IPD was obtained from 13 trials for 3990 patients, predominantly (97%) with 
reduced ejection fraction HF. Compared with control, there was a statistically significant 
difference in favour of ExCR for HRQoL and exercise capacity. At 12-month follow-up, 
improvements were seen in 6-minute walk test (mean: 21.0 metres, 95% CI: 1.57 to 40.4, 
p=0.034) and Minnesota Living with HF score (mean improvement: 5.9, 95% CI 1.0 to 10.9, 
p=0.018). No consistent evidence was found of differential intervention effects across patient 
subgroups. 
 
Conclusions: These results, based on an IPD meta-analysis of randomised trials confirms the 
benefit of ExCR on HRQoL and exercise capacity and supports the Class I recommendation 
of current international clinical guidelines that ExCR should be offered to all HF patients. 
 
Keywords: 
Rehabilitation, heart failure, quality of life, exercise capacity, QoL, MLHFQ
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Condensed Abstract 
 
The effect of exercise-based cardiac rehabilitation (ExCR) on HRQoL and exercise capacity 
for patients with heart failure was investigated using one- and two-stage meta-analysis on 
individual participant data from 13 randomised trials (3990 patients) 
 
At 12-month follow-up, improvements were seen in 6-minute walk test and Minnesota Living 
with HF score. No consistent evidence was found of differential intervention effects across 
patient subgroups. These results confirm the benefit of ExCR on HRQoL and exercise 
capacity, supporting the Class I recommendation of current international clinical guidelines 
that ExCR should be offered to all HF patients. 
 
 
Abbreviations 
CI  Confidence interval 
ExCR  Exercise-based cardiac rehabilitation 
HF   Heart failure 
HFpEF  HF with preserved ejection fraction (≥45% ejection fraction) 
HFrEF  HF with reduced ejection fraction (<45% ejection fraction) 
HRQoL Health-related quality of life 
IPD  Individual participant (or patient) data 
KCCQ  Kansas City Cardiomyopathy Questionnaire 
MLHFQ  Minnesota Living with Heart Failure Questionnaire 
Peak VO2  Peak oxygen uptake 
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Introduction 
 
Heart failure (HF) is a major public health problem with substantial morbidity and mortality 
and is a burden to patients and health systems. (1) Whereas survival after HF diagnosis has 
improved, prognosis remains poor; 30 to 40% of patients die within a year of diagnosis. (2) 
Patients living with HF experience marked reductions in their exercise capacity which has 
detrimental effects on their health-related quality of life (HRQoL). 
With increasing numbers of people living longer with symptomatic HF, the effectiveness and 
accessibility of health services for HF patients have never been more important. Exercise-
based cardiac rehabilitation (ExCR) is widely recommended in clinical guidelines as integral 
to the comprehensive care of HF patients. (3-7)  ExCR is a process by which patients, in 
partnership with health professionals, are encouraged and supported to achieve and maintain 
optimal physical health. (3) In addition to exercise training, it is now accepted that ExCR 
programmes should be comprehensive and include education and psychological care, as well 
as including advice on health and life-style behaviour change. (3, 4) 
Systematic reviews and trial level data meta-analyses have shown ExCR offers important 
health benefits for HF patients compared with control. (8-10) Based on data from 26 
randomised trials with median follow up of 12.4 months, Uddin et al reported a mean 
improvement in peak oxygen uptake (peak VO2) of 2.79ml/kg/min (95% CI: 2.05 to 3.53) 
following ExCR. (9) The 2014 Cochrane review reported a clinically important improvement 
across 13 RCTs in disease-specific health-related quality of life (HRQoL) as assessed by the 
Minnesota Living with Heart Failure Questionnaire (MLHFQ) up to 12-month follow-up 
(mean score -5.8 points, 95% CI: -9.2 to -2.4) compared with control. (8) Using meta-
regression analysis, these meta-analyses found no association between trial level patient 
characteristics (age, gender, ejection fraction) and ExCR on either exercise capacity or 
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HRQoL. However, such analyses are highly prone to study-level confounding (ecological 
fallacy) and should be interpreted with great caution. Uncertainty therefore remains as to 
whether there are differential effects of ExCR on exercise capacity and HRQoL across HF 
patient subgroups. (11) Individual participant data meta-analysis is increasingly be 
recognised as the gold standard approach for assessing intervention subgroup effects. (11, 12) 
Whilst a previous IPD meta-analysis (ExTraMATCH) reported the impact of ExCR on 
clinical events (death and hospitalisation) it did not consider the outcomes of exercise 
capacity or HRQoL. (13)    
Using IPD meta-analysis, this ExTraMATCH II study aimed to assess the impact of ExCR on 
HRQoL and exercise capacity and to investigate differential effects of ExCR across 
subgroups of patients with HF. 
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Methods 
 
This study was conducted and reported in accordance with the Preferred Reporting Items for 
a Systematic Review and Meta-analysis of Individual Participant Data (PRISMA IPD) 
statement and current guidance on the use of IPD.  (14, 15) Our full study protocol has been 
published elsewhere and is registered on the Prospero database of systematic review 
protocols (CRD42014007170). (16, 17) The clinical events results has been published 
elsewhere. (18) 
 
Search strategy and selection criteria  
 
Trials were identified from the original ExTraMATCH IPD meta-analysis carried out in 2004 
and updated with trials identified in the 2014 Cochrane systematic review of ExCR for HF. 
(8, 13) The Cochrane review searched the following electronic databases: Cochrane Central 
Register of Controlled Trials (CENTRAL) in The Cochrane Library, EMBASE, MEDLINE, 
CINAHL, PsycINFO, and the NHS Centre for Reviews and Dissemination (CRD). 
Conference proceedings were searched on Web of Science. Trial registers (Controlled-
trials.com and Clinicaltrials.gov) and reference lists of all eligible trials and identified 
systematic reviews were also checked. No language limitations were imposed. Details of the 
search strategy used are reported elsewhere. (16, 17) 
 
Trials were included if they met the following criteria: (i) randomised trials of adult patients 
(aged 18 years and older) with a diagnosis of HF with reduced ejection fraction (HFrEF) or 
HF with preserved ejection fraction (HFpEF) based on objective assessment of left 
ventricular ejection fraction and clinical findings; (ii) ExCR intervention that delivered an 
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aerobic exercise training component involving the lower limbs, lasting a minimum of 3 
weeks, either alone or as part of a comprehensive cardiac rehabilitation programme (which 
may also include health education and/or a psychological intervention); (iii) a comparator 
arm which did not prescribe an exercise intervention; (iv) a minimum follow-up of 6 months 
and (v) and a sample size of more than 50 (to ensure that the logistical effort in obtaining, 
cleaning and organising the data was commensurate with the contribution of the data set to 
the analysis). (19, 20)  
 
Data management 
 
Principal investigators of studies were invited by email to participate in this IPD meta-
analysis and share their anonymised trial data. Patients in the clinical trials providing data 
gave their consent on entry to the original clinical trial. All included datasets had ethical 
approval and consent from their sponsors; they were not required to seek additional ethical 
approval for the inclusion of their data in this analysis. The complete list of all requested 
variables and details on collaboration with principal investigators are reported in the study 
protocol. (8) Data from each trial were checked on range, extreme values, internal 
consistency, missing values, and consistency with published reports. Trial investigators were 
contacted about data discrepancies or missing information. Each anonymised dataset was 
saved in its original format and then converted and combined into one overall master dataset. 
All files were stored on a secure password protected computer server managed and in 
accordance with the data management standard operating procedures of Exeter Clinical Trials 
Unit, a UK Clinical Research Collaboration (UKCRC) registered clinical trials unit. Access 
to data at all stages of cleaning and analysis was restricted to the Exeter research team (OC, 
RST, SW and FCW). 
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Specification of outcomes, subgroups, and risk of bias assessment  
 
Health-related quality of life (HRQoL) and exercise capacity data were obtained from trial 
investigators at the patient level. HRQoL was recorded as one of three validated measures: (i) 
Minnesota Living with Heart Failure Questionnaire (MLHFQ) (21); (ii) Kansas City 
Cardiomyopathy Questionnaire (KCCQ) (22) and (iii) Guyatt Chronic Heart Failure scale 
(23). The first analysis was performed using only MLHFQ data; the second analysis used a 
standardised score calculated from any of the three measures above. As MLHFQ reports 
higher HRQoL as a lower score, the scales of the KCCQ and Guyatt Heart Failure score 
(which report higher HRQoL as a higher score) were reversed before standardising so that the 
directionality would be the same as MLHFQ. Therefore, for both the MLHFQ score and 
standardised HRQoL score, an improvement in HRQoL is shown by a reduction in the 
overall score. 
 
Exercise capacity was recorded as one of four validated exercise capacity measures: (i) peak 
VO2 (ml/kg/min); (ii) distance (metres) walked in a 6-minute walk test (6MWT); (iii) 
distance (metres) walked in an incremental shuttle walk test (ISWT) and (iv) cycle ergometer 
watts. Two of these measures, peak VO2 and 6MWT, analysed as separate outcomes. A third 
outcome, a standardised exercise capacity score for patients with any validated exercise 
capacity measure, was also analysed. The large HF-ACTION trial (24) provided data on both 
peak VO2 and 6MWT and was included in all analyses, with the peak VO2 measure taking 
precedence for the standardised exercise capacity score.  
We also sought IPD on the following pre-defined subgroups: age, gender, ejection fraction 
(HFpEF (≥45% ejection fraction) vs. HFrEF (<45% ejection fraction)), New York Heart 
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Association (NYHA) functional class, HF aetiology (ischaemic vs. non-ischaemic), ethnicity 
(white vs. non-white), and baseline exercise capacity. Study quality and risk of bias were 
assessed using the TESTEX quality assessment tool. (25)  
 
Statistical analysis 
 
A detailed statistical analysis plan was prepared (available from authors). All analyses were 
carried out according to the principle of intention to treat (i.e. patients analysed as 
randomised) and included all patients providing the data required for each model.  All one-
stage and two-stage analyses used random effects models as the overall dataset is likely to 
include a high degree of clinical heterogeneity across the individual trials due to differences 
in population, exercise-based rehabilitation intervention and comparator intervention. (26) 
All results are reported as a between group mean difference (ExCR-control) with a 95% 
confidence interval (CI) and p-value.  
 
The primary analyses comprised one-stage and two-stage IPD meta-analyses carried out at 
two follow-up times: 6 and 12 months. For all analyses, we used the observation at, or closest 
prior to, the analysis time. Using this criterion, more trials had available data at 12-month 
follow-up than at 6-month follow-up. Therefore, we have regarded the 12-month data 
analyses as being the primary analyses. The results at 12-month follow-up are reported ahead 
of the 6-month results in order to optimise the number of trials included.  
 
One-stage IPD models used a hierarchical random effects regression model, adjusted for the 
baseline value of the outcome measure. We ran a series of models to estimate the overall 
treatment effect and to investigate potential interactions between ExCR and pre-defined 
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patient subgroups (age, gender, left ventricular ejection fraction (< 45% or ≥ 45%), heart 
failure aetiology (ischaemic vs non-ischaemic), NYHA class (I/II vs III/IV) and baseline 
exercise capacity (16, 17)). Each model investigated one interaction effect only. We used 
two-stage random effects models as a sensitivity analysis to estimate the effect of ExCR.  The 
τ2 and I2 statistics were reported alongside the associated p-value for the results of the main 
analyses. 
 
The secondary analyses used a random effects hierarchical model which took account of the 
repeated measurement of the outcome (HRQoL or exercise capacity) over the duration of 
each trial.  These models utilised outcome data at all available time points. Adjustments for 
baseline values of the outcome measure were made; no other covariates were included in the 
model. This model included a time by treatment interaction term.  
To test the robustness of the primary analyses, pre-specified sensitivity analyses were carried 
out. First, each primary analysis was repeated after exclusion of the largest trial, HF-
ACTION. (24) Second, aggregate data from studies that did not provide IPD was added and 
the impact on meta-analysis conclusions assessed.  We checked for potential small study bias 
by assessing funnel plot asymmetry and using the Egger test. (27) Additional plots of the 
results of the one-stage IPD meta-analysis models, stratified by patient characteristics, are 
presented in order to give the reader a visual representation of the differential effect of ExCR 
in each subgroup. All analyses were undertaken using Stata 14.2 StataCorp LP, College 
Station, Texas, USA.  
 
Results 
Selection and inclusion of studies  
 
12 | P a g e  
 
Of the 23 trials identified either in the ExTraMATCH IPD meta-analysis (13) or the 2014 
Cochrane systematic review of ExCR for HF (8, 16), we were unable to include data from 
three trials (355 patients); for two trials data was no longer available (28, 29) and the 
investigators of the third trial could not be contacted. (30)  
 
Of the 20 trials remaining, one trial (31) was excluded due to an overlap between patients 
included in another identified trial. (32) Thirteen studies provided anonymised individual 
participant data (IPD) for analysis of HRQoL and exercise capacity outcomes. (24, 32-43) 
Published trial-level data was available for an additional five trials for each of the HRQoL 
(28, 29, 44-46) and exercise capacity analyses. (28-30, 44, 45) In addition to comparing usual 
care to an intervention arm of usual care plus ExCR, Gary (35) also compared the effects of 
cognitive behaviour therapy to cognitive behaviour therapy plus ExCR. For the purpose of 
analysis from this point forward, this will be described as one trial providing two comparators 
and be analysed as separate trials from this point forward. 
 
For the HRQoL analysis, 9 trials (including 10 comparator groups) provided data for 3000 
patients (1496 ExCR, 1504 control) with a median follow-up of 33 weeks. (24, 34, 35, 38-43) 
For the exercise capacity analysis, 13 trials (14 comparator groups) provided 3332 patients 
(1662 ExCR, 1670 control) with a median follow-up of 26 weeks. (24, 32-43) Figure 1 
summarises the study selection process.  
 
Study, patient, and trial characteristics 
Patient baseline characteristics were well balanced between ExCR and control patients (Table 
1). The majority of patients were male (73%) with a mean age of 61 years. The mean baseline 
left-ventricular ejection fraction was 27%; fewer than 3% of patients had preserved ejection 
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fraction heart failure (defined as ejection fraction > 45%). Most patients were in NYHA 
functional class II (62%) or III (36%).  Studies were published between 2000 and 2012 across 
Europe and North America. Sample size ranged from 50 to 2130 patients. All trials evaluated 
an aerobic exercise intervention; four also included resistance training. (34, 38, 40, 41) Four 
trials (five comparators) were conducted in an exclusively home-based setting (34, 35, 38, 
43); all other trials delivered ExCR in a centre-based setting. The dose of exercise training 
varied across studies; average session duration ranged from 15 to 60 minutes (including 
warm-up and cool-down); minimum number of sessions per week was 2, with a maximum of 
7; exercise intensity equivalent ranged from 40 to 70% peak VO2; and the duration of 
intervention ranged from 4 to 120 weeks. (Table 2) 
 
Quality of included trials 
 
The overall quality of included trials was judged to be moderate to good, with a median 
TESTEX (25) score of 11 (range 9 to 14) out of a maximum score of 15 (eTableOnline 
Appendix Table 1).  The criteria of allocation concealment and physical activity monitoring 
in the control groups were met in only two (24, 38) and three studies (24, 34, 42), 
respectively. The other TESTEX criteria were each met in at least 50% of trials.  
 
Effect of intervention on outcomes 
 
One-stage meta-analysis showed a significant improvement in HRQoL for those on the ExCR 
intervention compared with control, as assessed by the MLHFQ, at 12-month follow-up: 
(mean improvement: 5.9, 95% CI 1.0 to 10.9, p=0.018, τ2 =77, I2 =88%) (Online TableOnline 
Appendix Table 2) and standardised HRQoL score (mean improvement 0.20 standard 
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deviation units, 5% CI 0.03 to 0.37, p=0.020, τ2 =0.07, I2 =85%) (Online TableOnline 
Appendix Table 3). Similar results were seen at 6-month follow up. Two-stage meta-analysis 
results were comparable and are presented graphically for 612-month follow-up (Figure 2) 
and 612-month follow-up (Figure 3).  
 
Compared with control, treatment effects from the one-stage meta-analysis at 12-month 
follow-up showed a statistically significant improvement with ExCR in exercise capacity as 
assessed by 6MWT (mean difference: 21.0 metres, 95% CI: 1.6 to 40.4, p=0.034, τ2 = 491, I2 
=78%) (Online TableOnline Appendix Table 5) and standardised exercise capacity score 
(mean difference: 0.27 standard deviation units, 95% CI 0.11 to 0.43, p=0.001, τ2 =0.08, I2 
=91%) (Online TableOnline Appendix Table 6). No significant difference in peak VO2 at 12 
months was observed: 1.01 (95% CI -0.42 to 2.44, p=0.168, τ2 = 2.17, I2 =94%) (Online 
TableOnline Appendix Table 4).  
 
In the repeated measures analyses for each HRQoL and exercise capacity outcome, a 
significant interaction between ExCR and time was observed (Online FigureOnline Appendix 
Figure 1).  In sensitivity analyses, the results of the analyses excluding HF-ACTION, were 
broadly consistent with the overall results (Online Appendix eTables 3, 4, 5 and 6). Similar 
results were found with the addition of the trial-level aggregate data to the two-stage model at 
12-month follow-up. 
 
There was no evidence of significant small study bias for the five outcomes studied (Online 
FigureOnline Appendix Figure 2).  
 
Differential effects across subgroups  
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Analyses revealed no consistent interaction between the effect of ExCR and the predefined 
subgroups gender, ejection fraction, NYHA class, HF aetiology, ethnicity, and baseline 
exercise capacity for either HRQoL or exercise capacity (eTableOnline Appendix Tables 2, 3, 
4, 5 and 6 and Online FigureOnline Appendix Figures 3-4). 
 
A differential effect of ExCR across ages was observed in the standardised HRQoL score 
analysis at 6-month follow-up, with a differential reduction in HRQoL in the ExCR group 
compared with the control group (i.e. an increase in standardised HRQoL score) as age 
increased (0.006 standard deviation units, 95% CI 0.002 to 0.011, p=0.006) (Online 
TableOnline Appendix Table 3). To put this into context, based on a standard deviation of 24 
for MLHFQ score, this equates to a mean increase of 1.4 in MLHFQ score (ie: a reduction in 
HRQoL) for an increase of 10 years in patient age, in the ExCR group compared with the 
control group.  
 
Interaction analyses for the one-stage model at 12 months showed differential effects of 
ExCR by gender, with women showing greater benefit from ExCR than men for each of peak 
VO2  (0.57 ml/kg/min, 95% CI: 0.04 to 1.11, p=0.036) and 6MWT (14.9m, 95% CI: 1.2  to 
28.7, p=0.034) (Online TableOnline Appendix Table 4). Differential effects of ExCR were 
also seen between ethnic groups (Online TableOnline Appendix Table 5); white patients 
showed a greater improvement with ExCR in 6MWT distance compared with non-white 
patients: 14.2m (95% CI: 0.40 to 28.0, p=0.044).  
 
Discussion 
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We undertook an IPD meta-analysis to assess the impact of ExCR on exercise capacity and 
HRQoL in patients with HF. Analyses of data from 13 trials in 3990 randomised patients, 
predominantly (97%) with reduced ejection fraction HF, showed some evidence that ExCR 
improves both exercise capacity and HRQoL compared with no exercise control 12-month 
follow-up, with weaker evidence for a treatment effect at 6-month follow-up. The magnitude 
of the treatment effect of ExCR on MLHFQ score observed at 12-month follow-up was not 
only statistically significant but also clinically important, (47) with a mean between group 
difference of >5 points, favouring the ExCR group. Also, there was an increase of ≥ 16 
metres in the 6MWT in the ExCR group, which may also be clinically significant. (48) 
Interaction analyses showed that younger patients responded better to ExCR in terms of 
improved HRQoL; women and white patients had a better exercise capacity response. 
However, the interactions between ExCR and age, gender and ethnicity were not consistent 
across health outcomes, different analyses, and time points. The findings should therefore be 
considered hypothesis generating. 
 
We believe this to be the first IPD meta-analysis to assess the impact of ExCR on HRQoL 
and exercise capacity outcomes for patients with HF. The observed beneficial effects of 
ExCR on these outcomes are broadly consistent with previous trial-level (aggregate data) 
meta-analyses. (8-10, 49) The improvement (reduction) in MLHFQ score was similar to that 
reported by the 2014 Cochrane meta-analysis (5.8, 95% CI: 2.4 to 9.2). (8) The 
improvements in exercise capacity outcomes observed in our analyses were lower than those 
seen in trial-level meta-analyses (6MWT: 41.1 metres, 95% CI: 16.7 to 53.6 (31); peak VO2: 
2.79 ml/kg/min, 95% CI: 2.05 to 3.53). (9) We found no consistent evidence of HF patient 
subgroup effects, in accord with trial level meta-regression analyses. (8, 9) Within trial 
subgroup analyses from the HF-ACTION trial found no differential effect of ExCR on 
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HRQoL across patient characteristics. (50) A post-hoc analysis of the same trial cohort 
reported a significant interaction between ExCR and ethnic group with regard to 6MWT 
distance at 3-month follow-up (adjusted p=0.02), with mean improvement compared with 
control of 26m (95% CI: 18 to 34) in white HF patients versus 11m (95% CI: 0 to 21) in 
black HF patients, in the same direction as the current study. (51) 
 
Study limitations  
 
IPD meta-analysis has a number of strengths relative to traditional trial-level meta-analysis, 
including: reduction in ecological biases; the ability to check and transform data to common 
scores or measures; consistent methods of analysis across trials, and improved power to 
detect overall and subgroup effects. In this study, we used a one-stage meta-analysis 
approach to compare the outcomes between ExCR and control groups across all included 
trials. This approach adjusts the between-group comparisons of outcomes at follow-up for the 
baseline outcome score; this is important here as many of the included studies were small and 
therefore subject to chance differences in baseline score. Given these considerable 
advantages, meta-analyses that are based on IPD have been called the ‘gold standard’ of 
systematic review. (12) 
 
An increasingly recognised challenge of IPD meta-analysis is that of obtaining IPD from 
study investigators. (15, 52)  A recent systematic review across a total of 122 IPD meta-
analyses found the average meta-analysis located only 61% (95% CI: 46% to 74%) of eligible 
data sets. (53) In this study we were able to retrieve patient data for all 13 trials with exercise 
capacity data; HRQoL data was available in 9 out of 13 (69%) trials for 89% (2970/3332) of 
participants. Although our level of data retrieval compares favourably with this recent 
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systematic review, we recognise that incomplete data capture is a limitation of our study, 
which may have introduced bias to our HRQoL analyses.  Furthermore, we observed high 
levels of statistical heterogeneity for the outcomes of MLHFQ and 6MWT, likely to be due to 
the variation in population and intervention characteristics across the individual trials. 
Reassuringly, the inclusion of published results of trials for which no IPD was available did 
not change main effects. Due to limited published data on patient characteristics, we were 
unable to perform any sensitivity analyses using subgroup data. 
 
Further important limitations of this analysis were the small number of patients with HFpEF 
that contributed to this analysis and the lack of data on patient level ExCR ‘dose’. We did not 
have patient level data on ‘ExCR dose’ received, so we were unable to explore the effect of 
patient adherence to the rehabilitation program, or duration, frequency or intensity of ExCR 
undertaken by an individual patient.Trials that include larger proportions of patients with 
HFpEF would enable us to address the question of whether ExCR has a differential effect in 
such patients compared to those with HFrEF. Improved reporting of patient level data on 
adherence to ExCR will enable the investigation of any `dose–response’ effect of ExCR. 
With regard to generalisability and application to clinical practice, the average age of 
participants in this study was 61 years, whereas the average age of HF patients in practice is 
approximately 10 years older. (54)  
 
Conclusions 
 
Provision of ExCR to patients with HFrEF produces clinically important benefits in HRQoL 
and exercise capacity. Although we did observe some differences in the treatment effect of 
ExCR with age, gender, and ethnicity, these subgroup effects were not consistent across 
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outcomes, time points and analyses; hence, our findings do not endorse limiting ExCR 
interventions to subgroups of HF patients. However, due to the low numbers of women and 
non-white patients participating in ExCR, ExTraMATCH II would support the increasing 
representation of these groups. These results, based on an IPD meta-analysis of randomised 
trials, support the Class I recommendation of current international clinical guidelines that 
ExCR should be offered to all HF patients and the need to improve current poor uptake of 
ExCR in this population. Future data collection in this field requires a consensus on the 
definition, collection, and reporting of core outcomes, including a defined minimum 
standardised set of outcomes that should be measured and reported in all clinical trials in 
specific areas of health or health care. (55) Additionally we call for capture of data on patient 
level adherence to exercise training during the ExCR intervention period. Future trials should 
be extended to include more women, older patients and more patients with HFpEF, as well as 
patients with comorbid conditions. More generally, the research community should continue 
to implement policies that encourage primary study authors to make their datasets available, 
either by depositing their datasets in publicly available repositories or sharing with IPD meta-
analysis collaborations when directly requested. 
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Perspectives: 
Competency in Medical Knowledge: Exercise-based cardiac rehabilitation improves 
HRQoL and exercise capacity in patients with heart failure, irrespective of patient 
characteristics.  
 
Translational Outlook 1: Future trials need to evaluate the effect of exercise-based cardiac 
rehabilitation in patient groups more representative of the current population of patients with 
heart failure.  
 
Translational Outlook 2: A consensus on the definition, collection and reporting of core 
outcomes in all clinical trials should be reached. 
 
Translational Outlook 3: Individual participant data on adherence to exercise-based cardiac 
rehabilitation should be collected in randomised controlled trials. 
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Figure legends 
Figure 1: PRISMA-IPD flow diagram 
A PRISMA-IPD (Preferred Reporting Items for Systematic Reviews and Meta-Analyses of 
Individual Participant Data) flow diagram to show selection and synthesis of ExTraMATCH 
II study data. 
 
CENTRAL ILLUSTRATION: (Please see separate document for how we would like Figure 
2 presented as the Central Illustration) 
Figure 2. Effect of ExCR on HRQoL and exercise capacity at 12 months: two-stage IPD 
meta-analysis 
A Forest plot from the two-stage IPD meta-analysis model to show the effect of ExCR on 
HRQoL and exercise capacity at 12 months 
The black circle is centred on the point estimate of the effect of ExCR in each trial, with the 
horizontal line showing the 95% confidence interval (CI) of this estimate. An arrow to either 
the left or right shows that the CI extends beyond the area shown in the Forest Plot. The size 
of the grey square around the point estimate is proportional to the weight that the individual 
trial contributes to the meta-analysis. The diamond and vertical red line show the overall 
estimate of the effect of ExCR in the two-stage meta-analysis. 
2a: Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
2b. All HRQoL measures (standardised score)      
2c. Peak VO2, directly reported 
2d. 6MWT, directly reported 
2e. All exercise capacity measures (standardised score) 
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Figure 32. Effect of ExCR on HRQoL and exercise capacity at 6 months: two-stage IPD 
meta-analysis 
The black circle is centred on the point estimate of the effect of ExCR in each trial, with the 
horizontal line showing the 95% confidence interval (CI) of this estimate. An arrow to either 
the left or right shows that the CI extends beyond the area shown in the Forest Plot. The size 
of the grey square around the point estimate is proportional to the weight that the individual 
trial contributes to the meta-analysis. The diamond and vertical red line show the overall 
estimate of the effect of ExCR in the two-stage meta-analysis. 
 32a: Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
32b. All HRQoL measures (standardised score)      
32c. Peak VO2, directly reported 
32d. 6MWT, directly reported 
32e. All exercise capacity measures (standardised score) 
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Figure 3. Effect of ExCR on HRQoL and exercise capacity at 12 months: two-stage IPD 
meta-analysis 
3a: Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
3b. All HRQoL measures (standardised score)      
3c. Peak VO2, directly reported 
3d. 6MWT, directly reported 
3e. All exercise capacity measures (standardised score) 
 
Online Figure 1. Effect of ExCR on HRQoL and exercise capacity 
Online Figure 1a: Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
Online Figure 1b. All HRQoL measures (standardised score)      
Online Figure 1c. Peak VO2, directly reported 
Online Figure 1d. 6MWT, directly reported 
Online Figure 1e. All exercise capacity measures (standardised score) 
 
Online Figure 2: Funnel plots (12 months) 
Online Figure 2a: Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
Footnote: Egger test -1.40, p=0.656 
Online Figure 2b. All HRQoL measures (standardised score)      
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Footnote: Egger test -0.72, p=0.577 
Online Figure 2c. Peak VO2, directly reported 
Footnote: Egger test 0.99, p=0.665 
Online Figure 2d. 6MWT, directly reported 
Footnote: Egger test 1.71, p=0.150 
Online Figure 2e. All exercise capacity measures (standardised score) 
Footnote: Egger test 1.85, p=0.214 
 
Online Figure 3: Effect of ExCR on HRQoL across patient subgroups (12 months) 
Online Figure 3a: Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
Online Figure 3b. All HRQoL measures (standardised score)      
 
Online Figure 4: Effect of ExCR on exercise capacity across patient subgroups 
Online Figure 4a. Peak VO2, directly reported 
Online Figure 4b. 6MWT, directly reported 
Online Figure 4c. All exercise capacity measures (standardised score) 
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Tables 
Table 1: Baseline characteristics of patients 
 Characteristic ExCR 
(n=1,662) 
Control 
(n=1,670) 
All  
(n=3,332) 
Age (years); mean (SD) 60.9 (13.2) 61.2 (13.5) 61.1 (13.4) 
Gender  
   Male 
   Female 
 
1,187 (71.4) 
475 (28.6) 
 
1,237 (74.1) 
433 (25.9) 
 
2,424 (72.8) 
908 (27.3) 
Baseline ejection fraction (%); mean (SD) 27.0 (8.8) 26.9 (8.7) 26.9 (8.8) 
Baseline ejection fraction: 
   HFrEF (< 45%) 
   HFpEF (≥ 45%) 
 
1,721 (96.8) 
57 (3.2) 
 
1,744 (97.5) 
45 (2.5) 
 
3,465 (97.1) 
102 (2.9) 
NYHA status  
   Class I 
   Class II 
 
20 (1.2) 
1,002 (61.2) 
 
25 (1.5) 
1,032 (62.8) 
 
45 (1.4) 
2,034 (62.0) 
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   Class III 
   Class IV 
597 (36.5) 
19 (1.2) 
569 (34.6) 
18 (1.1) 
1,166 (35.5) 
37 (1.1) 
Aetiology  
   Ischaemic  
   Non-ischemic 
 
892 (54.9) 
732 (45.1) 
 
884 (54.1) 
750 (45.9) 
 
1,776 (54.5) 
1,482 (45.5) 
Ethnicity 
   White 
   Non-white 
 
1,085 (69.3) 
480 (30.7) 
 
1,117 (70.9) 
458 (29.1) 
 
2,202 (70.1) 
938 (30.0) 
MLHFQ; mean (SD) 35.6 (23.7) 33.6 (25.6) 34.6 (24.7) 
Peak VO2 (ml/kg/min); mean (SD) 15.0 (4.5) 15.1 (4.7) 15.0 (4.6) 
6MWT (metres); mean (SD) 362.6 (109.3) 362.5 (112.1) 362.6 (110.7) 
 
HFrEF: Heart Failure with reduced Ejection Fraction; HFpEF: Heart Failure with preserved Ejection Fraction; NYHA: New York Heart 
Association classification; MLHFQ: Minnesota Living with Heart Failure Questionnaire; peak VO2: peak oxygen uptake; 6MWT: 6-minute walk 
test.
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Table 2. Characteristics of included studies and interventions 
Study characteristics n (%) of 14 comparators 
Publication year 
   1990 to 1999 
   2000 to 2009 
   2010 to 2012 
   Unpublished 
 
0 (0) 
9 (64) 
5 (36) 
0 (0) 
Main study location 
   Europe   
   North America* 
 
9 (64) 
5 (36) 
Single study centre 
   Single 
   Multiple  
 
10 (71) 
4 (29) 
Sample size 
   0 to 99 
   100 to 999 
   1000 and over 
 
8 (57) 
5 (36) 
1 (7) 
Duration of latest follow up (weeks); median (range) 
   HRQoL outcomes 
   Exercise capacity outcomes 
 
33 (26 to 104) 
26 (9 to 520) 
Intervention characteristics 
Intervention type 
   Exercise only programs 
   Comprehensive programs 
 
9 (64) 
5 (36) 
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Type of exercise 
   Aerobic exercise only 
   Aerobic plus resistance training  
 
10 (71) 
4 (29) 
Dose of intervention  
   Duration of intervention (weeks), median (range) 
   Frequency (sessions per week), median (range) 
   Length of exercise session (mins), median (range) 
   Exercise intensity, range 
 
 
24 (4 to 120) 
3 (2 to 7) 
30 (15 to 60) 
40-70% peak VO2 
11-15 Borg rating 
Setting 
   Centre-based only 
   Home-based only 
 
9 (64) 
5 (36) 
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Belardinelli 
(2012) 
1 0 0 1 0 3 1 1 1 0 0 1 9 
Dracup 
(2007) 
1 0 0 1 0 3 1 2 1 1 1 1 10 
Gary (2010) 1 1 0 1 1 3 1 2 1 0 0 0 11 
Giannuzzi 
(2003) 
1 0 0 1 0 2 1 2 1 0 1 1 10 
Hambrecht 
(2000) 
1 1 0 1 0 3 0 2 1 0 1 1 11 
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HF-Action 
(2008) 
1 1 1 1 1 3 1 2 1 1 0 1 14 
Jolly (2009) 1 1 1 1 0 2 1 2 1 0 1 1 12 
Mueller 
(2007) 
1 0 0 1 0 2 1 2 1 0 1 1 10 
Nilsson 
(2008) 
1 1 0 1 1 2 1 2 1 0 0 1 11 
Passino 
(2006) 
1 0 0 1 0 2 1 2 1 0 1 1 10 
Witham 
(2005) 
1 1 0 1 1 3 1 2 1 0 1 0 12 
Witham 
(2012) 
1 1 0 1 1 3 1 2 1 0 1 0 12 
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Yeh (2011) 1 1 0 1 1 3 1 2 1 1 0 0 12 
(1) Three points possible; (2) If ITT was not specifically mentioned, but it was noted that no participants withdrew and all analysed, the analysis was 
considered to be ITT. 
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Online Table 2. Minnesota Living with Heart Failure Questionnaire (MLHFQ) - overall treatment effect and subgroups effects 
 Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
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Overall effect -2.85 (-5.85, 
0.14), 
p=0.062 
-1.73 (-4.15, 
0.70), 
p=0.163 
-5.94 (-10.87, -
1.01), p=0.018 
-5.73 (-
12.38, 0.93), 
p=0.091 
Not applicable to MLHF analyses as HF-Action  
only supplied KCCQ scores 
Age 
(years) 
0.12 (-0.10, 
0.35), 
p=0.280 
 0.01 (-0.20, 
0.22), p=0.912 
     
Gender 
(male vs 
female) 
-5.31 (-11.01, 
0.39), 
p=0.068 
 -1.49 (-6.95, 
3.96), p=0.592 
     
Ejection 
fraction (%) 
0.22 (-0.14, 
0.58), 
p=0.227 
 0.24 (-0.07, 
0.56), p=0.127 
     
Ejection 
Fraction 
4.06 (-11.0, 
19.1), 
 8.02 (-3.29, 
19.3), p=0.165 
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(HFpEF vs 
HFrEF) 
p=0.597 
NYHA class  
(NYHA III/IV  
vs NYHA I/II) 
-6.38 (-12.31, 
-0.45), 
p=0.035 
 -5.30 (-10.9, 
0.24), p=0.061 
     
HF aetiology 
(ischaemic vs 
non-ischaemic) 
4.67 (-1.65, 
11.0), 
p=0.147 
 2.08 (-3.64, 
7.80), p=0.477 
     
Ethnic group  
(white vs non-
white) 
3.15 (-4.31, 
10.6), 
p=0.408 
 5.17 (-2.19, 
12.5), p=0.169 
     
Exercise capacity        
Peak VO2 0.24 (-0.82,  0.47 (-0.35,      
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directly 
measured 
1.31), 
p=0.654 
1.29), p=0.262 
Peak VO2, 
directly 
measured and 
predicted 
0.72 (-0.01, 
1.45), 
p=0.053 
 0.62 (-0.02, 
1.26), p=0.058 
     
HFpEF: Heart Failure with preserved Ejection Fraction; HFrEF: Heart Failure with reduced Ejection Fraction; NYHA: New York Heart 
Association classification; peak VO2: peak oxygen uptake.
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Online Table 3. Standardised Health-related Quality of Life (HRQoL) measure- overall treatment effect and subgroups effects 
 Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
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Overall effect -0.11 (-0.16, 
-0.06), 
p<0.001 
-0.10 (-0.15, -
0.05), 
p<0.001 
-0.20 (-0.37, -
0.03), p=0.020 
-0.19 (-0.38, 
-0.01), 
p=0.043 
-0.11 (-0.24, 
0.01), 
p=0.069 
-0.08 (-0.18, 
0.02), 
p=0.131 
-0.17 (-0.28, 
-0.07), 
p=0.001 (*) 
-0.21 (-0.45, 
0.04), 
p=0.106 
Age 
(years) 
0.006 (0.002, 
0.011), 
p=0.006 
 0.001 (-0.004, 
0.005), 
p=0.734 
 0.003 (-0.007, 
0.014), 
p=0.536 
 -0.001 (-
0.011, 
0.008), 
p=0.788 
 
Gender 
(male vs 
female) 
0.050 (-
0.068, 
0.168), 
p=0.407 
 0.018 (-0.105, 
0.140), 
p=0.775 
 -0.223 (-
0.469, 0.024), 
p=0.077 
 -0.106 (-
0.335, 
0.123, 
p=0.365 
 
Ejection 
fraction (%) 
-0.000 (-
0.007, 
0.007), 
 -0.004 (-0.011, 
0.004), 
p=0.340 
 0.010 (-0.006, 
0.025), 
p=0.225 
 0.010 (-
0.003, 
0.023), 
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p=0.963 p=0.150 
Ejection 
Fraction 
(HFpEF vs 
HFrEF) 
-0.03 (-0.46, 
0.41), 
p=0.902 
 0.13 (-0.26, 
0.53), p=0.505 
 0.16 (-0.47, 
0.84), 
p=0.581 
 0.34 (-0.14, 
0.81), 
p=0.163 
 
NYHA class  
(NYHA III/IV  
vs NYHA I/II) 
-0.013 (-
0.126, 
0.100), 
p=0.824 
 0.031 (-0.086, 
0.149), 
p=0.599 
 -0.126 (-
0.380, 0.129), 
p=0.334 
 -0.082 (-
0.314, 
0.151), 
p=0.491 
 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.076 (-
0.036, 
0.187), 
p=0.182 
 0.030 (-0.085, 
0.145), 
p=0.611 
 0.220 (-0.055, 
0.494), 
p=0.117 
 0.080 (-
0.162, 
0.322), 
p=0.517 
 
Ethnic group  0.041 (-  0.017 (-0.108,  0.173 (-0.172,  0.243 (-  
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(white vs non-
white) 
0.079, 
0.161), 
p=0.506 
0.142), 
p=0.787 
0.519), 
p=0.325 
0.086, 
0.573), 
p=0.147 
Exercise capacity        
Peak VO2 
directly 
measured 
-0.002 (-
0.014, -
0.011), 
p=0.775 
 0.008 (-0.005, 
0.021), 
p=0.230 
 0.012 (-0.035, 
0.059), 0.612 
 0.021 (-
0.012, 
0.055), 
p=0.216 
 
Peak VO2, 
directly 
measured and 
predicted 
0.000 (-
0.012, 
0.013), 
p=0.956 
 0.008 (-0.004, 
0.021), 
p=0.208 
 0.023 (-0.010, 
0.056), 
p=0.171 
 0.020 (-
0.008, 
0.048), 
p=0.172 
 
Standardised 
scores using 
N/A as no further data available over analysis in row above 
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peak VO2, 
6MWT, ISWT 
units, and watts 
(*) Fixed effect on treatment with a random effect on study, due to non-convergence of the random treatment effect model. 
HFpEF: Heart Failure with preserved Ejection Fraction; HFrEF: Heart Failure with reduced Ejection Fraction; NYHA: New York Heart 
Association classification; peak VO2: peak oxygen uptake; 6MWT: 6-minute walk test; ISWT: incremental shuttle walk test. 
 
 
Online Table 4. Peak oxygen uptake (peak VO2), directly measured - overall treatment effect and subgroups effects 
 Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
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Overall effect 0.62 (-0.82, 
2.07), 
p=0.397 
0.69 (-0.24, 
1.62), 
p=0.145 
1.01 (-0.42, 
2.44), p=0.168 
1.14 (-0.05, 
2.34), 
p=0.061 
0.71 (-1.10, 
2.52), 
p=0.444 
0.77 (-0.73, 
2.28), 
p=0.315 
1.15 (-0.60, 
2.90), 
p=0.196 
1.26 (-0.31, 
2.82), 
p=0.115 
Age 
(years) 
0.00 (-0.02, 
0.02), 
p=0.980 
 -0.00 (-0.02, 
0.14), p=0.646 
 -0.01 (-0.07, 
0.04), 
p=0.628 
 -0.02 (-0.06, 
0.03), 
p=0.415 
 
Gender 
(male vs 
female) 
-0.25 (-0.78, 
0.27), 
p=0.345 
 -0.57 (-1.11, -
0.04), p=0.036 
 -0.67 (-2.47, 
1.14), 
p=0.468 
 -0.42 (-1.80, 
0.95), 
p=0.549 
 
Ejection 
fraction (%) 
0.03 (0.00, 
0.06), 
p=0.034 
 0.02 (-0.01, 
0.05), p=0.157 
 0.05 (-0.04, 
0.13), 
p=0.280 
 0.03 (-0.04, 
0.11), 
p=0.349 
 
Ejection 
Fraction 
0.07 (-1.88, 
2.01), 
 -0.13 (-2.07, 
1.81), p=0.897 
 -1.34 (-2.42, 
5.09), 
 -0.19 (-3.34, 
2.97), 
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(HFpEF vs 
HFrEF) 
p=0.947 p=0.485 p=0.907 
NYHA class  
(NYHA III/IV  
vs NYHA I/II) 
-0.10 (-0.58, 
0.38), 
p=0.687 
 -0.25 (-0.75, 
0.24), p=0.318 
 -0.50 (-2.13, 
1.13), 
p=0.549 
 -0.75 (-1.95, 
0.46), 
p=0.224 
 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.02 (-0.44, 
0.47), 
p=0.945 
 -0.13 (-0.60, 
0.34), p=0.577 
 -0.63 (-2.04, 
0.79), 
p=0.386 
 -0.24 (-1.39, 
0.91), 
p=0.683 
 
Ethnic group  
(white vs non-
white) 
-0.19 (-0.66, 
0.29), 
p=0.447 
 -0.07 (-0.58, 
0.45), p=0.800 
 -0.47 (-2.36, 
1.43), 
p=0.628 
 0.16 (-1.71, 
2.03), 
p=0.870 
 
Exercise capacity        
Peak VO2 0.01 (-0.04,  0.03 (-0.03,  -0.06 (-0.21,  -0.04 (-0.17,  
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directly 
measured 
0.06), 
p=0.719 
0.08), p=0.332 0.09), 
p=0.435 
0.10), 
p=0.602 
Peak VO2, 
directly 
measured and 
predicted 
0.01 (-0.04, 
0.06), 
p=0.702 
 0.03 (-0.02, 
0.08), p=0.299  
 
 -0.06 (-0.21, 
0.09), 
p=0.452 
 
 -0.03 (-0.16, 
0.10), 
p=0.660 
 
 
HFpEF: Heart Failure with preserved Ejection Fraction; HFrEF: Heart Failure with reduced Ejection Fraction; NYHA: New York Heart 
Association classification; peak VO2: peak oxygen uptake. 
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Online Table 5. 6MWT directly measured - overall treatment effect and subgroups effects 
 Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
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Overall effect 22.1 (1.87, 
42.3), 
p=0.032 
24.4 (6.13, 
42.6), 
p=0.009 
21.0 (1.57, 
40.4), p=0.034 
24.0 (5.30, 
42.7), 
p=0.012 
22.1 (-1.64, 
45.8), 
p=0.068 
27.9 (1.25, 
54.6), 
p=0.040 
24.0 (1.25, 
46.7), 
p=0.039 
29.0 (3.05, 
55.0), 
p=0.029 
Age 
(years) 
0.01 (-0.49, 
0.50), 
p=0.973 
 -0.03 (-0.56, 
0.50), p=0.911 
 0.45 (-0.81, 
1.72), 
p=0.482 
 0.97 (-0.23, 
2.17), 
p=0.115 
 
Gender 
(male vs 
female) 
-10.7 (-23.6, 
2.26), 
p=0.106 
 -14.9 (-28.7, -
1.16), p=0.034 
 -19.7 (-47.3, 
7.92), 
p=0.162 
 -13.5 (-39.9, 
12.9), 
p=0.317 
 
Ejection 
fraction (%) 
0.34 (-0.46, 
1.14), 
p=0.399 
 0.21 (-0.64, 
1.06), p=0.634 
 1.05 (-0.78, 
2.88), 
p=0.262 
 0.04 (-1.69, 
1.77), 
p=0.963 
 
Ejection 
Fraction 
0.68 (-47.8, 
49.2), 
 15.4 (-36.3, 
67.0), p=0.560 
 13.8 (-6.09, 
88.6), 
 14.7 (-56.1, 
85.4), 
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(HFpEF vs 
HFrEF) 
p=0.978 p=0.717 p=0.685 
NYHA class  
(NYHA III/IV  
vs NYHA I/II) 
-1.81 (-14.3, 
10.6), 
p=0.776 
 1.31 (-12.0, 
14.6), p=0.847 
 -5.90 (-34.6, 
22.8), 
p=0.687 
 -8.14 (-35.7, 
19.4), 
p=0.563 
 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
3.73 (-8.26, 
15.7), 
p=0.542 
 -4.30 (-17.1, 
8.51), p=0.510 
 37.9 (9.34, 
66.4), 
p=0.009 
 26.9 (-0.13, 
54.0), 
p=0.051 
 
Ethnic group  
(white vs non-
white) 
10.46 (-2.55, 
23.5), 
p=0.115 
 14.2 (0.40, 
28.0), p=0.044 
 -20.7 (-60.5, 
19.0), 
p=0.307 
 8.34 (-29.5, 
46.1), 
p=0.665 
 
Exercise capacity        
6MWT directly -0.05 (-0.11,  0.19 (-0.08,  -0.06 (-0.18,  -0.05 (-0.16,  
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measured 0.01), 
p=0.079 
0.46), p=0.176 0.06), 
p=0.321 
0.07), 
p=0.421 
HFpEF: Heart Failure with preserved Ejection Fraction; HFrEF: Heart Failure with reduced Ejection Fraction; NYHA: New York Heart 
Association classification; 6MWT: 6-minute walk test. 
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Online Table 6. Standardised exercise capacity score - overall treatment effect and subgroups effects 
 Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
Two-stage 
model,  
12 months 
FU 
Mean 
difference 
(95% CI) 
p-value 
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p-value 
Overall effect 0.230 (0.067, 
0.392), 
p=0.006 
0.256 (0.116, 
0.396), 
p<0.001 
0.268 (0.110, 
0.426), 
p=0.001 
0.302 
(0.142, 
0.462), 
p<0.001 
0.256 (0.079, 
0.433), 
p=0.005 
0.278 
(0.105, 
0.451), 
p=0.002 
0.298 
(0.125, 
0.471), 
p=0.001 
0.324 (0.150, 
0.497), 
p<0.001 
Age 
(years) 
0.001 (-
0.003, 
0.004), 
p=0.758 
 -0.001 (-0.005, 
0.003), 
p=0.636 
 0.003 (-0.008, 
0.014), 
p=0.565 
 -0.000 (-
0.010, 
0.009), 
p=0.948 
 
Gender 
(male vs 
-0.063 (-
0.157, 
0.319), 
 -0.096 (-0.197, 
0.006), 
p=0.065 
 -0.066 (-
0.250, 0.118), 
p=0.484 
 -0.065 (-
0.240, 
0.110), 
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female) p=0.194 p=0.464 
Ejection 
fraction (%) 
0.007 (0.001, 
0.012), 
p=0.021 
 0.005 (-0.001, 
0.011), 
p=0.108 
 0.008 (-0.003, 
0.019), 
p=0.131 
 0.008 (-
0.003, 
0.018), 
p=0.169 
 
Ejection 
Fraction 
(HFpEF vs 
HFrEF) 
0.11 (-0.20, 
0.43), 
p=0.487 
 0.06 (-0.28, 
0.40), p=0.733 
 0.21 (-0.23, 
0.65), 
p=0.348 
 0.06 (-0.36, 
0.49), 
p=0.766 
 
NYHA class  
(NYHA III/IV  
vs NYHA I/II) 
-0.010 (-
0.098, 
0.079), 
p=0.826 
 -0.043 (-0.138, 
0.052), 
p=0.377 
 -0.011 (-
0.184, 0.162), 
p=0.900 
 -0.061 (-
0.224, 
0.101), 
p=0.459 
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HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.012 (-
0.074, 
0.098), 
p=0.783 
 0.024 (-0.070, 
0.117), 
p=0.620 
 0.035 (-0.143, 
0.213), 
p=0.701 
 0.049 (-
0.121, 
0.219), 
p=0.573 
 
Ethnic group  
(white vs non-
white) 
-0.064 (-
0.159, 
0.031), 
p=0.187 
 0.018 (-0.088, 
0.124), 
p=0.741 
 -0.096 (-
0.352, 0.160), 
p=0.461 
 0.078 (-
0.195, 
0.351), 
p=0.577 
 
Exercise capacity        
Standardised 
scores using 
peak VO2, 
6MWT, ISWT 
units, and watts 
-0.025 (-
0.066, 
0.017), 
p=0.240 
 -0.017 (-0.048, 
0.508), 
p=0.105 
 -0.070 (-
0.147, 0.007), 
p=0.077 
 -0.052 (-
0.129, 
0.026), 
p=0.191 
 
Formatted: Space After:  10 pt
Formatted: Space After:  10 pt
Formatted: Space After:  10 pt
Formatted: Space After:  10 pt
65 | P a g e  
 
 
Peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test 
